Synthon BV (batch release)
UkraineAll drugs from this manufacturer
-
The drug is intended to reduce elevated platelet levels in patients at high risk of developing essential thrombocythemia if current treatment is ineffective or not tolerated by the patient.
Dosage form: capsules, hard
Active substance Dosage anagrelide 0.5 mg ATC: L01XX35
-
The drug is used for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), as well as for adjuvant therapy (prevention of recurrence) of RCC after surgery. It is also prescribed for the treatment of progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules, hard
Active substance Dosage sunitinib 37.5 mg ATC: L01XE04
-
The drug is used for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), as well as for adjuvant therapy of RCC and the treatment of progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules, hard
Active substance Dosage sunitinib 12.5 mg ATC: L01XE04
-
The drug is used for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), as well as for adjuvant therapy of RCC and the treatment of progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules, hard
Active substance Dosage sunitinib 25 mg ATC: L01XE04
-
The drug is used for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), as well as neuroendocrine tumors of the pancreas. It is also used as adjuvant therapy for adults at high risk of RCC recurrence after surgery.
Dosage form: capsules, hard
Active substance Dosage sunitinib 50 mg ATC: L01XE04